Aquestive Therapeutics narrows Q1 loss, secures $150M debt facility
Aquestive Therapeutics reported a first-quarter EPS loss of $0.07, beating the consensus estimate of $0.14 and narrowing from $0.24 a year earlier. The company secured a $150 million debt facility, expanded its sales force 50% to 75 representatives and reaffirmed plans to resubmit its Anaphylm NDA in Q3 2026.
1. Q1 Financial Performance
Aquestive recorded a first-quarter net loss of $0.07 per share, outperforming the consensus estimate of $0.14 and improving from a $0.24 loss in Q1 2025.
2. Anaphylm Resubmission Timeline
Following a Type A FDA meeting, the company reaffirmed plans to resubmit its Anaphylm (dibutepinephrine) sublingual film NDA in the third quarter of 2026, targeting an accelerated review.
3. Financing and Cash Runway
Aquestive entered into a $150 million debt facility with Oaktree Capital Management to bolster its balance sheet and extend operational runway through key development milestones.
4. Commercial and Clinical Progress
The company expanded its planned field force by 50% to approximately 75 sales representatives, completed a Phase 1 AQST-108 topical gel study without safety issues, and advanced global regulatory strategies.